Glucagon-like peptide (GLP)-1 stimulate insulin secretion and inhibit the secretion of glucagon, also has a certain effect of relieving NASH, authors observed that subcutaneous injection of Semaglutide in NASH patients could achieve NASH regression (131). This evidence concerns the gene GCG and metabolic dysfunction-associated steatohepatitis.